By Josh Beckerman

The U.S. Food and Drug Administration expanded its emergency use authorization for a combination of two Eli Lilly & Co. monoclonal antibodies for treating mild to moderate Covid-19, expanding authorization to all ages including newborns for those who are at high risk for progression to severe Covid-19.

The combination of bamlanivimab and etesevimab was previously authorized for people 12 years of age and older weighing at least 40 kilograms.

Lilly said it is "working quickly to understand neutralization activity of our therapies on the Omicron variant of concern."

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

12-03-21 1518ET